阿替利珠单抗-贝伐珠单抗降期后肝移植治疗中晚期肝细胞癌的疗效
这项前瞻性II期研究评估了中晚期肝细胞癌患者经阿替利珠单抗-贝伐珠单抗降期后行肝移植的疗效。16例超出扩展移植标准的患者中,26%获得移植资格,2年无复发生存率和移植后总生存率分别为90%和94%,急性排斥反应似有增加但临床可控。
要点
- Atezo-Bev降期可使部分超出扩展移植标准的中晚期HCC患者获得肝移植机会。
- 移植后2年无复发生存率90%、总生存率94%,急性排斥反应增加但可控。
- 对免疫治疗有应答的HCC患者应考虑肝移植。
核心结论
- Atezo-Bev降期后肝移植在中晚期超出常规移植标准的HCC中取得有前景的无复发生存。
- 急性排斥反应似有增加但临床可控,对免疫治疗有应答的HCC患者应考虑肝移植。
研究设计与样本
- 前瞻性II期研究,纳入16例超出扩展移植标准、不适合进一步局部治疗的中晚期HCC患者。
- 患者先接受阿替利珠单抗-贝伐珠单抗降期治疗,主要终点为无复发生存,安全性和有效性为次要结局。
- 纵向研究肿瘤组织和外周血的频谱定量病理和免疫特征。
主要发现
- 16例患者中位肿瘤大小6.5 cm(IQR 3-8),中位AFP 283 ng/ml(IQR 6-1,080),门静脉癌栓占50%。
- 中位降期时间4.7个月(IQR 2.4-7.6),15例(94%)既往接受过局部治疗。
- 移植前免疫相关不良事件3例(19%),移植后急性排斥反应4例(25%)。
- 移植后90天并发症发生率和死亡率分别为62.5%(95%CI 35-85%)和6.3%(95%CI 0.2-30%)。
- 移植物病理显示10例完全缓解、6例部分缓解,随访期间1例(6.2%)HCC复发,2年无复发生存率和移植后总生存率分别为90%和94%。
临床怎么用
- 对Atezo-Bev降期后应答的中晚期HCC患者,可考虑肝移植。
- 移植前需平衡免疫治疗相关不良事件尤其是移植物排斥风险与生存获益。
- 排斥反应可用标准类固醇和强化早期免疫抑制管理。
局限性
- 样本量小(16例),随访时间中位16个月(95%CI 4-22),需更长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver transplantation (LT) is a curative treatment option in early and intermediate hepatocellular carcinoma (HCC) following downstaging with locoregional therapies (LRT). Tumor response to immune checkpoint inhibitors may extend LT eligibility to intermediate and advanced stages. METHODS: In this prospective phase II study, patients with intermediate and advanced HCCs beyond extended transplant criteria, not amenable to further LRTs, were downstaged with atezolizumab-bevacizumab (Atezo-Bev) prior to LT. The primary endpoint was recurrence-free survival with safety and efficacy as additional outcomes. Spectral quantitative pathology and immune signatures in tumor tissue and peripheral blood were studied longitudinally. RESULTS: Sixteen patients with HCC beyond expanded transplant criteria (median tumor size 6.5 cm [IQR 3-8], median AFP 283 ng/ml [IQR 6-1,080], portal vein thrombosis 50%) were downstaged to LT after a median of 4.7 months (IQR 2.4-7.6). Prior LRTs were used in 15 (94%) patients. The washout period from the last Atezo-Bev dose to transplant was 57.5 (IQR 29-87) days. Median follow-up was 16 months (95% CI 4-22). Pre-transplant immune-related adverse events occurred in 3 (19%) patients and post-transplant acute rejection in 4 (25%). Post-LT 90-day morbidity and mortality were 62.5% (95% CI 35-85%) and 6.3% (95% CI 0.2-30%) respectively. Explant pathology revealed 10 complete and 6 partial responses. Responding patients harboured a tumor microenvironment with features suggestive of immune activation/extinguishment, correlated with duration of Atezo-Bev treatment and length of pre-LT washout. One (6.2%) HCC post-LT recurrence occurred during follow-up. Recurrence-free and post-transplant overall survival were 90% and 94% after 2 years, respectively. CONCLUSIONS: LT following Atezo-Bev downstaging achieves promising recurrence-free survival in intermediate and advanced HCC beyond conventional transplant criteria. Acute rejection seemed to be increased but was clinically manageable. LT should be considered in patients with HCC who respond to immunotherapy. IMPACT AND IMPLICATIONS: Immune checkpoint inhibitors are now standard treatment for advanced hepatocellular carcinoma (HCC) and some intermediate-stage cases. Emerging evidence suggests that immunotherapy may also have a role in the neoadjuvant setting before liver resection or transplantation. By inducing tumor responses, immunotherapy may downstage patients initially ineligible for curative therapies, enabling liver transplantation (LT) and favorable post-transplant outcomes. However, treatment-related adverse events, particularly graft rejection, must be balanced against potential survival benefits. In this first prospective study evaluating LT after atezolizumab-bevacizumab (Atezo-Bev) in patients with intermediate or advanced HCC not amenable to other therapies, 26% achieved transplant eligibility. Two-year post-LT outcomes were comparable to those observed with conventional transplant criteria. Immune monitoring indicated that tumor response and graft rejection are closely linked through the PD-1/PD-L1 pathway. Although rejection risk appeared increased, it was manageable with standard steroids and intensified early immunosuppression. These findings support considering expanded transplant criteria in selected patients with sustained responses to immunotherapy. REGISTRATION NUMBER: NCT05879328.
引用
- Bhoori S, Rivoltini L, Pinato DJ, et al. Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL). J Hepatol. 2026. PMID: 41763363. doi:10.1016/j.jhep.2026.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。